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BACKGROUND. The pineal hormone melatonin has been shown to exert a direct oncostatic
activity on neoplastic cells, particularly from breast cancer. In the present study, we evaluated
the effects of melatonin on the proliferation and on the cell cycle distribution of human
androgen-independent DU 145 prostate cancer cells. Experiments were also performed to
gain insights into the possible mechanism of action of the hormone.
METHODS. The effects of melatonin on DU 145 cell proliferation was analyzed by counting
the cells by hemocytometer at the end of treatment. The effects of the pineal hormone on cell
cycle distribution were evaluated by FACS analysis. RT-PCR studies were performed to detect
Mel1a and Mel1b expression in DU 145 cells. The cellular localization of 125I-melatonin binding
sites was investigated by radioreceptor assay. A commercially available binding-protein assay
kit was utilized to evaluate intracellular cAMP levels.
RESULTS. Melatonin, in physiological doses, significantly inhibited DU 145 cell proliferation
and induced cell cycle withdrawal by accumulating cells in G0/G1 phase. The mRNA for
Mel1a receptors was found to be expressed in DU 145 cells; however, by radioreceptor assay,
no binding sites for 125I-melatonin could be detected in membrane preparations, suggesting
that, in these cells, the level of translation of this mRNA is too low to possibly mediate the
antiproliferative action of the hormone. In agreement with this hypothesis, melatonin did not
affect forskolin-induced intracellular cAMP accumulation. Binding sites for 125I-melatonin
were found in nuclear extracts of DU 145 cells.
CONCLUSIONS. Melatonin exerts a direct oncostatic activity on human androgen-
independent prostate cancer cells, by affecting cell cycle progression. This activity seems to be
mediated by nuclear, but not by membrane, receptors. Prostate 45:238–244, 2000.
© 2000 Wiley-Liss, Inc.
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INTRODUCTION
Melatonin, the indolic hormone produced by the
pineal gland, is known to participate in the control of
many physiological processes, including circadian
rhythms, sexual reproduction, aging, and immune
function [1]. During the last few years, experimental
evidence has been accumulating, to indicate a link be-
tween melatonin and the growth of neoplastic tissues
[2]. Modulation of pineal gland function has been
shown to affect tumor growth in experimentally in-
duced breast cancer [3]; moreover, nocturnal secretion
of melatonin is reduced in a number of human malig-
nancies [4–6]. Although these effects might be related
to either the free radical scavenging or immunostim-
ulatory activity of the hormone, several reports in the
literature strongly support the hypothesis that mela-
tonin might also exert a direct antiproliferative action
at the level of the tumor tissue, particularly of breast
cancer [7,8].
In a recent paper, we showed that melatonin sig-
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nificantly inhibits the growth of the human androgen-
sensitive LNCaP prostate cancer cell line [9]. It is well
known that prostate carcinoma, which is usually an-
drogen-dependent in its early phases, very often pro-
gresses to a condition in which the androgen depen-
dence is lost [10]. While androgen withdrawal
represents the most common and successful therapy
for the pathology in its early stages [11], the therapeu-
tic options for the more advanced, steroid-resistant
prostate carcinoma are still very limited [10]. In the
present study, we analyzed the effects of melatonin
on: 1) the proliferation, and 2) the cell cycle distribu-
tion of human androgen-independent (DU 145) pros-
tate cancer cells. Experiments were also performed to
gain insights into the possible mechanism of action of
the hormone, since the molecular mechanisms under-




Melatonin was purchased from Sigma Chemical
Co. (St. Louis, MO); 2-[125I]iodomelatonin was ob-
tained from NEN-Life Science Products (Milan, Italy).
Cell Culture
The cell line DU 145 was obtained from the Ameri-
can Type Culture Collection (Rockville, MD). These
cells were derived from a brain metastasis of a human
androgen-unresponsive prostate carcinoma; they re-
tain the androgen independence of the original tumor
and do not express the androgen receptor [12]. DU 145
cells (passages 60–70) were routinely grown in RPMI-
1640 medium (Seromed Biochrom, Berlin, Germany)
supplemented with 5% fetal bovine serum (FBS, Life
Technologies, Paisley, Scotland, UK), glutamine (1
mmol/l), and antibiotics (100 U/ml penicillin G so-
dium and 100 mg/ml streptomycin sulfate) in a hu-
midified atmosphere of 5% CO2-95% air. Under these
conditions, the doubling time was 36 hr.
Cell Proliferation Studies
Cell growth studies were performed on exponen-
tially growing cells. DU 145 cells were plated at a den-
sity of 300 cells/cm2 in 100-mm dishes. Treatment
started 2 days after plating. Cells were treated every
day with melatonin (0.01–100 nM) for 7 days. At the
end of treatment, cells were harvested and counted by
hemocytometer.
FACS Analysis
Fluorescence-activated cell sorting (FACS) analysis
was performed as described [13]. DU 145 cells were
plated at a density of 4,000 cells/cm2 in 100-mm
dishes in RPMI-1640 supplemented with 5% FBS.
Twenty-four hours after plating, cells were treated ei-
ther with vehicle or with melatonin (0.01, 1, and 100
nM) for 48 hr. After treatment, DU 145 cells were tryp-
sinized, washed twice with ice-cold PBS, fixed by
dropwise addition of 70% ethanol, and incubated at
4°C overnight with constant agitation. Thirty minutes
before flow cytometric analysis, the cellular double-
stranded nucleic acids were stained with propidium
iodine (50 mg/ml). RNAse (100 units/ml) was in-
cluded to degrade double-stranded RNA. Propidium
iodine fluorescence was obtained using linear ampli-
fication with doublet discrimination. Five thousand
forward scatter-gated events were collected per
sample. Data were analyzed by the Cellquest program
(Becton Dickinson, San Jose, CA).
Mel1a and Mel1b Expression by RT-PCR
In order to determine whether membrane (Mel1a
and Mel1b) receptors are expressed in prostate cancer
cells, RT-PCR was performed on RNA extracts from
DU 145 cells and HEK293 (positive control). After phe-
nol-chloroform extraction, 1 mg of total RNA from
each sample was used in a reverse transcription reac-
tion. cDNA synthesis was performed using the Gene
AMP kit (Perkin Elmer Cetus, Norwalk, CT), with an
oligo(dT)16 as a primer for the reverse transcriptase.
Samples containing cDNAs obtained from cells were
then amplified in a 100-ml solution containing PCR
buffer (50 mM KCl, 10 mM Tris-HCl), 2 mM MgCl2,
100 pmoles of a pair of specific primers, and 2.5 U Taq
Polymerase. Thirty-five cycles of amplification were
performed in a programmable heat block (Perkin
Elmer Cetus) (90 sec denaturation at 94°C, 90 sec
primer annealing at 54°C, and 2 min primer extension
at 72°C). The primers were: 58-CTGGCCTGCGTCCT-
CATCTTCACCATCGTG-38 (sense, 88–117) and 58-
CCATGCTGGCGGGGTCAGAGGC-38 (antisense,
784–805) for Mel1a [14], and 58-CGCTGTCCGCGGT-
GCTCATCGTCACCACC-38 (sense, 125–153) and 58-
CCAGGGCCCAGCCGTCATAGAAGATG-38 (anti-
sense, 300–325) for Mel1b [14]. After RT-PCR, the
amplified DNA products were separated on a 1.5%
agarose gel and stained with ethidium bromide.
Southern blotting analysis was performed, and blots
were hybridized with synthetic 32P-labeled oligo-
nucleotide probes: 58-TGCGTTCCTGAGCTTCTT-
GTTCCGATACAC-38 (154–183) for Mel1a [14], and 58-
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TGCGTTCCGGAGCTTGCGGTTCCTGAGCAC-38
(193–222) for Mel1b [14].
Melatonin-Binding Studies
Experiments were performed to clarify the cellular
(nuclear vs. membrane) localization of melatonin
binding sites in prostate cancer cells. To this purpose,
nuclear and membrane preparations were obtained
from DU 145 cells as previously described [15], with
slight modifications. Briefly, cells were harvested with
PBS and centrifuged at 4,000g for 10 min. Cell pellets
were resuspended in sucrose 0.32 M, homogenized
with an Ultra-turrax homogenizer, and then centri-
fuged at 800g for 10 min at 4°C. The nuclear pellets
were gently resuspended in 10 mM Tris-HCl/Triton
X-100 0.1% (pH 7.6). The resulting supernatants, con-
taining the membranes, were then centrifuged at
48,000g for 30 min at 4°C. The membrane pellets were
washed and resuspended in 10 mM Tris-HCl buffer.
Melatonin binding assays were performed as de-
scribed [16], combining both saturation and displace-
ment protocols in the same curve. By effectively com-
bining both saturation and competition protocols in
the same curve, one can reach high concentrations of
ligand without consuming excessive amounts of la-
beled ligand (competition part of the curve), yet have
adequate radioactivity in the lower concentration
range (saturation part of the curve). The saturation
part of the curve was performed by incubating mem-
brane or nuclear preparations (100 ml) with 2-[125I]io-
domelatonin (5 × 10−13–10−9 M, 100 ml) in a total vol-
ume of 300 ml. The competition part of the curve was
performed by incubating membrane or nuclear prepa-
rations (100 ml) with 2-[125I]iodomelatonin (10−9 M,
100 ml) in the presence of unlabeled melatonin (10−9–
10−6M, 100 ml) in a total volume of 300 ml. After 2 hr
incubation at room temperature, 1 ml ice-cold assay
buffer was added, and the tubes were immediately
centrifuged at 48,000g for 30 min for membranes, and
at 800g for 10 min for nuclear preparations. Superna-
tants were discarded and pellets were counted in a
g-counter. Simultaneous analysis of the data from the
saturation and competition protocols for the same
curves was performed by the Ligand program [17].
The protein content of each membrane or nuclear
preparation was evaluated according to the method of
Bradford [18].
cAMP Assay
Intracellular cyclic AMP accumulation was mea-
sured over a 15-min incubation period of subconfluent
DU 145 cells, with 5 mM forskolin (Sigma Chemical
Co.) as activator of adenylcyclase in the absence or in
the presence of melatonin (1 nM), after a 15-min pre-
incubation with the phosphodiesterase inhibitor 3-iso-
butyl-1-methil-xantine (0.5 mM) (Sigma Chemical
Co.). A commercially available binding-protein assay
kit (Amersham, Milan, Italy) was used to evaluate
cAMP levels in ethanol extracted cells, according to
the manufacturer’s instructions.
Statistical Analysis
The data from experiments involving cell prolifera-
tion and cAMP formation were analyzed according to
the test of Dunnett [19], after one-way analysis of vari-
ance.
RESULTS
Effects of Melatonin on Cell Proliferation
The effects of treatment with melatonin (0.01–100
nM) on DU 145 cell growth are reported in Figure 1. In
DU 145 cells, melatonin significantly inhibited cell
proliferation when utilized in nanomolar concentra-
tions (0.5–5 nM). Lower (0.01 and 0.1 nM) or higher (10
and 100 nM) doses of the hormone were found to be
ineffective (Fig. 1).
Effects of Melatonin on Cell Cycle Distribution
To analyze in more detail the antiproliferative ac-
tion of melatonin on DU 145 cells, we evaluated the
possible effect of the hormone in the control of cell
cycle progression. By FACS scan analysis, we showed
that treatment with melatonin (1 nM) caused a signifi-
cant accumulation of cells in G0/G1 phase and a de-
crease in the S phase of the cell cycle (Table I). A lower
Fig. 1. Effects of melatonin on the proliferation of DU 145 cells.
Results are expressed as mean cell number per plate ± SE. Results
are representative of four separate experiments. C, controls with-
out melatonin. *P < 0.05 vs. C.
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(0.01 nM) and a higher (100 nM) dose were ineffective
(Table II).
RT-PCR of Human Mel1a and Mel1b Melatonin
Receptor Transcripts
The expression of membrane receptors for melato-
nin in DU 145 prostate cancer cells was evaluated by
RT-PCR, utilizing primers specific for Mel1aand Mel1b
cDNAs.
Figure 2 shows that a Mel1a-specific cDNA (718 bp)
could be amplified and identified by Southern blot in
DU 145 cells (Fig. 2, lane 2). The same band was de-
tected in the positive control (human embryonic kid-
ney cell line HEK293, Fig. 2, lane 3). No amplification
product was seen in samples in which the reverse
transcriptase was omitted (Fig. 2, lane 1). RT-PCR for
Mel1b mRNA did not yield any amplification product,
indicating that prostate cancer cells do not seem to
express this melatonin membrane receptor, at least
when evaluated by RT-PCR.
Melatonin Binding Sites in DU 145 Cells
Experiments were performed to verify the presence
of melatonin binding sites and to clarify their cellular
localization. To this purpose, binding experiments
were performed on both membrane and nuclear
preparations from DU 145 cells, using 2-[125I]io-
domelatonin as the ligand. No detectable binding
could be observed in membrane preparations. On the
contrary, the results obtained from homologous bind-
ing curves showed specific 2-[125I]iodomelatonin
binding in nuclear preparations. Computer analysis of
the data revealed that in DU 145 cells, 2-[125I]io-
domelatonin interacts with a single class of nuclear
binding sites, with a Kd value of 4.4 × 10−10 M and a
Bmax value of 42 fmoles/mg protein (Fig. 3).
Effects of Melatonin on cAMP Accumulation in
DU 145 Cells
Membrane receptors for melatonin are known to be
coupled to the activation of Gi proteins and to a de-
crease of intracellular levels of cAMP [20,21]. These
studies were undertaken to determine whether, in
prostate cancer cells, melatonin could modify forsko-
lin-induced accumulation of cAMP. As indicated in
Table II, melatonin failed to prevent the stimulation of
cAMP synthesis induced by forskolin in DU 145 cells.
DISCUSSION
The data reported in this paper demonstrate that
doses of melatonin, corresponding to the physiologi-
cal concentrations in blood (nanomolar range), signifi-
cantly inhibit the growth of the human androgen-
independent DU 145 prostate cancer cell line.
Moreover, the pineal hormone affects cell cycle distri-
bution, accumulating cells in G0/G1 phase, while de-
creasing the number of cells in S phase. This indicates
that the antiproliferative action of melatonin is not due
to a cytotoxic effect on these cells, but rather to a modi-
fication of the cell cycle length. In agreement with
these observations, we recently reported [9] an anti-
TABLE I. Effects of Melatonin on Cell Cycle Distribution








G1 48 ± 1.02 52 ± 1.00 56 ± 0.25* 50 ± 0.50
S 22 ± 0.25 19 ± 0.70 15 ± 0.60* 21 ± 0.25
G2-M 28 ± 1.30 28 ± 0.95 27 ± 0.41 28 ± 1.05
*P < 0.05 vs. controls.
TABLE II. Effects of Melatonin on Forskolin-Induced
Stimulation of cAMP Synthesis*
Treatment Concentration cAMP concentration
Controls 16.6 ± 3.6
Forskolin 5 mM 302.3 ± 31.8
Melatonin 1 nM 11.3 ± 5.8
Forskolin + melatonin 5 mM + 1 nM 398.2 ± 37.3
*Cultures were treated with forskolin and/or melatonin for 15
min. cAMP levels were determined as described in Materials
and Methods and are expressed as pmoles/plate. The data are
the mean ± SE of four experiments, each performed in quadru-
plicate.
Fig. 2. Autoradiography of RT-PCR products obtained from DU
145 cells (lane 2) after gel electrophoresis, Southern blotting, and
hybridization with a specific 32P-labeled oligonucleotide Mel1a
probe. No amplification product could be detected in samples in
which the reverse transcriptase was omitted (lane 1). Lane 3,
positive control (human embryonic kidney cell line, HEK293).
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proliferative action of the indolic hormone on the hu-
man androgen-sensitive LNCaP prostate cancer cell
line. Thus, melatonin seems to exert a direct cytostatic
action on prostate cancer cells, independent of their
dependence on testicular steroids.
A direct interaction between melatonin and pros-
tate cancer was previously proposed, although contro-
versial results have been reported. Melatonin has been
shown to inhibit the growth of R3327H Dunning pros-
tate adenocarcinoma [22] but to enhance the growth of
a transplantable androgen-insensitive prostatic adeno-
carcinoma in rats [23]. Physiological concentrations of
the hormone inhibit 3H-thymidine incorporation in
androgen-sensitive LNCaP prostate cancer cells [24];
in androgen-insensitive PC3 prostate cancer cells, mel-
atonin differently affects 3H-thymidine incorporation
according to cell density [25], stimulating it at low cell
density and attenuating it in high-density cultures
[25]. At present, the reasons for the partial discrepancy
between these observations and the data reported in
our paper are unclear. However, they might be ac-
counted for by the different experimental conditions
adopted (e.g., cell lines, cell culture conditions).
On the other hand, consistent with the data here
reported, a direct oncostatic action of melatonin has
been demonstrated in a variety of tumor cells other
than prostate cancer. Physiological, but nor subphysi-
ological or pharmacological, concentrations of melato-
nin have been shown to exert a direct antiproliferative
effect on human estrogen-responsive MCF-7 breast
cancer cells [7,26,27]. The pineal hormone also inhibits
the growth of the human ovarian adenocarcinoma
BG-1 cell line [28], of human neuroblastoma SK-N-SH
cells [29], of murine colon 38 adenocarcinoma cells
[30], and of rat melanoma [31] or pheocromocitoma
[32] cells.
It is interesting that, in breast cancer, melatonin is
able to exert its antimitogenic action on estrogen-
dependent, but not on hormone-unresponsive, cells.
In estrogen-dependent breast cancer cells, the pineal
hormone appears to act mainly by interfering with the
estrogen response system [33–35]. In contrast, accord-
ing to our observations, melatonin can inhibit the
growth of both androgen-dependent [9] and andro-
gen-independent (data here reported) prostate cancer
cells. Experiments are in progress in our laboratory to
clarify whether the pathways through which the hor-
mone exerts its cytostatic activity might be similar in
the two different cell models.
In spite of the several reports supporting a direct
cytostatic effect of melatonin on cancer cells, the signal
transduction pathway mediating this activity is still
unknown. In this paper, we have shown that, in DU
145 cells, Mel1a membrane receptors are expressed at
the mRNA level; however, by radioreceptor assays, no
binding sites for 125I-melatonin could be detected in
membrane preparations. We concluded that the level
of translation of Mel1a mRNA was too low to possibly
mediate a physiological effect. This conclusion is fur-
ther supported by the observation that melatonin does
not affect forskolin-induced cAMP accumulation. It is
actually well-known that ligand-induced activation of
membrane Mel1a receptors is followed by decreased
intracellular cAMP formation [20,21]. On the other
hand, we have shown that binding sites for 125I-
melatonin can be detected in the nuclear fraction of
DU 145 cells, suggesting that the oncostatic activity of
this hormone might be mediated, at least partially, by
receptors localized in the nucleus. We recently re-
ported similar results on androgen-sensitive LNCaP
prostate cancer cells [9]. The hypothesis of a nuclear
site of action of melatonin is supported by previous
observations made in breast cancer cells. First, little to
no melatonin binding has been found in MCF-7 breast
cancer cell membranes [36]. Second, melatonin has
been reported to inhibit the binding of the estradiol-
estrogen receptor complex to the estrogen response
element in nuclear extracts of MCF-7 cells [35]. Ac-
cording to the authors, these observations suggest the
presence, in nuclear extracts, of a receptor for melato-
nin, which is able to interfere with the binding to DNA
of the activated estrogen receptor. In this context, it is
important to note that physiological actions of mela-
tonin, other than the oncostatic one, have been pro-
posed to be nuclear receptor-mediated [37,38].
Although increasing attention has recently been de-
voted to the “putative” nuclear receptor for melatonin,
its identity remains unknown. Melatonin binding to
Fig. 3. Specific binding of 2-[125I]melatonin to nuclear prepara-
tions from DU 145 cells. The binding assay was performed as
described in Materials and Methods. The binding isotherms were
analyzed by the LIGAND program, and the binding parameters
(Bmax and Kd) were determined. One representative curve, out of
four binding experiments, is reported.
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the orphan nuclear receptor RZR/RORa has been
demonstrated by transient transfection assays in Dro-
sophila cells [39–41]. RZR/RORa receptors have been
suggested to mediate the effects of melatonin in the
control of cell growth and differentiation. However,
the possibility that this transcription factor might be
the nuclear receptor for melatonin is still a matter of
debate [42,43]. Calmodulin has been suggested as an-
other potential candidate receptor for melatonin [35].
It was previously demonstrated that calmodulin may
facilitate the binding of activated steroid receptors to
their specific DNA response element [35,44]. On the
other hand, the pineal hormone has been shown to
bind to calmodulin in a Ca++-dependent fashion, re-
sulting in inhibition of calmodulin [45,46].
In conclusion, the data here reported indicate that
melatonin exerts cytostatic activity on human andro-
gen-independent DU 145 prostate cancer cells, by af-
fecting cell cycle progression. This activity seems to be
nuclear, but not membrane, receptor-mediated. Addi-
tional studies are needed to identify the receptor in-
volved in the oncostatic property of melatonin.
Our results, together with previous reports on dif-
ferent human neoplasms, seem to suggest that mela-
tonin might be considered as an effective cytostatic
agent, either alone or in combination with standard
anticancer treatments. This hypothesis is further sup-
ported by the well-known immunostimulatory and
antioxidant properties of the hormone.
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